WASHINGTON — A stark contrast in approaches to pharmaceutical regulation and public health messaging was on display Tuesday at a forum hosted by the Pharmaceutical Research and Manufacturers of America (PhRMA), highlighting tensions within the administration of Health Secretary Robert F. Kennedy Jr. The event featured differing perspectives from two of Kennedy’s key appointees: Centers for Medicare and Medicaid Services Administrator Mehmet Oz and Food and Drug Administration Commissioner Marty Makary.
The forum underscored the complex dynamic Kennedy faces as he navigates the intersection of industry interests, scientific rigor, and public trust. While Kennedy has been critical of the pharmaceutical industry and has questioned vaccine safety, his administration includes figures with varying degrees of alignment with those views. The event, intended to foster dialogue, instead revealed a clear divide in how to address ongoing challenges in the healthcare landscape, particularly regarding vaccine confidence and regulatory processes.
Oz, known for his past television appearances and promotion of alternative medicine, engaged in a cordial conversation with Pfizer CEO and PhRMA board chair Albert Bourla. According to attendees, Oz spoke positively about the benefits of vaccines and expressed openness to private meetings with industry executives to develop policy proposals. He even suggested that individuals with experience in the pharmaceutical sector should consider serving in government roles, a position seemingly at odds with Kennedy’s frequent criticism of the “revolving door” between the public and private sectors. This stance raises questions about the administration’s commitment to transparency and independence from industry influence.
FDA Scrutiny and the Moderna Flu Vaccine Dispute
In contrast to the collaborative tone of Oz’s discussion, FDA Commissioner Marty Makary faced pointed questions from Bertha Coombs, a former CNBC reporter, regarding the agency’s increasingly skeptical approach to vaccine regulation. The scrutiny centered on the recent decision by a top FDA official, Vinay Prasad, to decline review of Moderna’s application for a new influenza vaccine. The FDA’s refusal to review the application, as reported by STAT News, has sparked debate about the agency’s standards for evaluating vaccine safety and efficacy.
Makary’s defense of Prasad’s decision reportedly focused on the need for rigorous scientific evidence and a cautious approach to approving new vaccines. However, Coombs pressed him on whether the agency’s heightened skepticism could hinder innovation and limit access to potentially life-saving treatments. The exchange highlighted a growing tension within the FDA, with some officials advocating for a more conservative regulatory approach while others emphasize the importance of expediting the approval of new medical products. This internal debate reflects a broader shift in the agency’s priorities under Kennedy’s leadership.
Industry Response and the Search for Common Ground
PhRMA, representing leading pharmaceutical companies, has been actively seeking to engage with the Kennedy administration to address its concerns and shape policy discussions. The forum provided an opportunity for industry leaders to present their perspectives and build relationships with key officials. Albert Bourla, as PhRMA board chair, emphasized the industry’s commitment to innovation and its willingness to collaborate with the government to improve public health. However, the contrasting viewpoints expressed by Oz and Makary suggest that finding common ground may prove challenging.
The situation is further complicated by Kennedy’s own history of questioning the safety and efficacy of vaccines. In January 2026, Pfizer CEO Albert Bourla publicly criticized Kennedy’s stance on vaccines, attributing declining vaccination rates in the U.S. To “anti-science” rhetoric. Bourla’s comments, reported by Fierce Pharma, underscore the deep divisions that exist between the pharmaceutical industry and some segments of the public health community.
Navigating a Divided Landscape
The PhRMA forum revealed a complex and evolving landscape within the Kennedy administration. The differing approaches of Oz and Makary reflect a broader debate about the role of government regulation, the importance of scientific evidence, and the need to address public concerns about vaccine safety. As the administration moves forward, it will be crucial to navigate these tensions and forge a coherent policy agenda that promotes both innovation and public health.
The FDA’s decision regarding the Moderna flu vaccine application is likely to be a key test case for the agency’s new approach to vaccine regulation. The outcome of this review will have significant implications for the future of vaccine development and could further exacerbate tensions between the pharmaceutical industry and the Kennedy administration. The situation also comes as PhRMA leaders prepare to meet with former President Donald Trump in 2025, according to Fierce Pharma, adding another layer of political complexity to the debate.
Looking ahead, the administration’s next major checkpoint will be the release of its proposed budget for the Department of Health and Human Services, expected in March. This budget will provide a clearer indication of the administration’s priorities and its commitment to addressing the challenges facing the healthcare system.
This is a developing story. Share your thoughts and perspectives in the comments below.
Related reading
